PARADIGM-HF:沙库巴曲缬沙坦治疗中无症状与症状性低血压的差异及获益
该研究为PARADIGM-HF的事后分析,纳入8399例射血分数降低的心衰患者,比较沙库巴曲缬沙坦与依那普利在发生低血压亚组中的疗效与安全性。结果显示,无论有无低血压,沙库巴曲缬沙坦对主要结局的获益均维持,且在症状性低血压患者中交互作用显著(P=0.01)。
要点
- 低血压(无论无症状或症状性)均与更差结局相关。
- 沙库巴曲缬沙坦的获益在低血压患者中未减弱,症状性低血压者甚至更显著。
- 沙库巴曲缬沙坦因不良事件停药率低于依那普利,低血压患者亦然。
核心结论
- 沙库巴曲缬沙坦或依那普利治疗期间发生的无症状和症状性低血压均与更差结局相关,但沙库巴曲缬沙坦的获益在低血压患者中维持甚至增强。
研究设计与样本
- PARADIGM-HF的事后分析,纳入8399例射血分数降低的心衰患者,采用时间更新Cox比例风险模型评估沙库巴曲缬沙坦对比依那普利的疗效与安全性。
主要发现
- 8399例患者中,1343例(16.0%)仅发生无症状性低血压,936例(11.1%)至少发生一次症状性低血压。
- 症状性低血压患者较仅无症状性低血压患者年龄更大、心血管合并症更多,而无症状性低血压患者左心室射血分数更低。
- 沙库巴曲缬沙坦对比依那普利的主要结局HR:无低血压0.80(95%CI 0.72-0.89),无症状性低血压0.87(95%CI 0.70-1.08),症状性低血压0.51(95%CI 0.38-0.69),Pinteraction=0.01。
- 心血管死亡和全因死亡的分析结果与主要结局一致,安全性在有无低血压患者中均维持。
- 在无症状性和症状性低血压患者中,沙库巴曲缬沙坦组因不良事件停药较依那普利组更少。
临床怎么用
- 治疗期间出现低血压不应成为停用沙库巴曲缬沙坦的理由,其获益在低血压患者中仍维持。
局限性
- 本研究为PARADIGM-HF的事后分析,低血压分组非随机化,可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypotension is an important clinical problem in heart failure (HF). OBJECTIVES: This study sought to examine the association between asymptomatic vs symptomatic hypotension and outcomes in PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). METHODS: In a post hoc analysis of PARADIGM-HF, the efficacy and safety of sacubitril/valsartan compared to enalapril were estimated using time-updated Cox proportional hazards models. The primary outcome was cardiovascular death or HF hospitalization. RESULTS: Among 8,399 patients in PARADIGM-HF, 1,343 (16.0%) experienced only asymptomatic hypotension, and 936 (11.1%) experienced symptomatic hypotension at least once after randomization. Patients with symptomatic hypotension were older and more frequently had cardiovascular comorbidities compared to those developing only asymptomatic hypotension. By contrast, left ventricular ejection fraction was lower in those with asymptomatic hypotension. Patients who experienced either type of hypotension were at higher risk for all outcomes examined. However, the effect of sacubitril/valsartan on the primary outcome was not diminished in patients experiencing hypotension compared to those who did not: the HR for sacubitril/valsartan vs enalapril was 0.80 (95% CI: 0.72-0.89) for no hypotension, 0.87 (95% CI: 0.70-1.08) for asymptomatic hypotension, and 0.51 (95% CI: 0.38-0.69) for symptomatic hypotension (Pinteraction = 0.01), and this was also true for cardiovascular and all-cause deaths. The safety of sacubitril/valsartan vs enalapril was also maintained regardless of the occurrence of hypotension. Discontinuation of randomized treatment was less common with sacubitril/valsartan vs enalapril in patients experiencing asymptomatic and symptomatic hypotension. CONCLUSIONS: Although both asymptomatic and symptomatic hypotension during treatment with sacubitril/valsartan or enalapril were associated with worse outcomes, the benefits of sacubitril/valsartan were maintained (or even enhanced) in patients experiencing hypotension.
引用
- Matsumoto S, Shen L, Henderson AD, et al. Asymptomatic vs Symptomatic Hypotension With Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction in PARADIGM-HF. J Am Coll Cardiol. 2024. PMID: 39320292. doi:10.1016/j.jacc.2024.08.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。